API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Also known as: Elzovantinib, Tpx-0022, 2271119-26-5, Elzovantinib [inn], Tty12q00ly, Unii-tty12q00ly

Molecular Formula

C₂₀H₂₀FN₇O₂

Molecular Weight

409.4 g/mol

InChI Key

UUDPUQDMSHQSKH-NSHDSACASA-N

FDA UNII

TTY12Q00LY

Elzovantinib is an orally bioavailable, multi-targeted kinase inhibitor with potential antineoplastic activity. Upon oral administration, elzovantinib binds to and inhibits three tyrosine kinases that are often overexpressed in a variety of cancer cell types, including MET (c-Met; hepatocyte growth factor receptor; HGFR) , Src, and colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; macrophage colony-stimulating factor receptor; M-CSFR) thereby disrupting their respective signaling pathways. MET, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis. Src, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. CSF1R is a cell-surface receptor for colony stimulating factor 1 (CSF1); this receptor tyrosine kinase is overexpressed by tumor-associated macrophages (TAMs) in the tumor microenvironment (TME), and plays a major role in both immune suppression and the induction of tumor cell proliferation.

1 2D Structure

TPX0022

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(11S)-16-amino-2-ethyl-6-fluoro-11-methyl-14-oxo-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaene-5-carbonitrile

2.1.2 InChI

InChI=1S/C20H20FN7O2/c1-3-27-10-13-12(8-22)14(21)4-5-15(13)30-11(2)9-24-20(29)17-18(23)26-28-7-6-16(27)25-19(17)28/h4-7,11H,3,9-10H2,1-2H3,(H2,23,26)(H,24,29)/t11-/m0/s1

2.1.3 InChI Key

UUDPUQDMSHQSKH-NSHDSACASA-N

2.1.4 Canonical SMILES

CCN1CC2=C(C=CC(=C2C#N)F)OC(CNC(=O)C3=C4N=C1C=CN4N=C3N)C

2.1.5 Isomeric SMILES

CCN1CC2=C(C=CC(=C2C#N)F)O[C@H](CNC(=O)C3=C4N=C1C=CN4N=C3N)C

2.2 Other Identifiers

2.2.1 UNII

TTY12Q00LY

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Elzovantinib

2. Tpx-0022

3. 2271119-26-5

4. Elzovantinib [inn]

5. Tty12q00ly

6. Unii-tty12q00ly

7. Tpx002

8. Schembl20694441

9. Gtpl11869

10. Tpx0022

11. Tpx-0022 [who-dd]

12. Ex-a5131

13. Nsc820832

14. S9620

15. Nsc-820832

16. Compound 5 [wo2019023417a1]

17. Hy-111787

18. Cs-0091874

19. (11s)-16-amino-2-ethyl-6-fluoro-11-methyl-14-oxo-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaene-5-carbonitrile

2.4 Create Date

2019-03-16

3 Chemical and Physical Properties

Molecular Formula	C₂₀H₂₀FN₇O₂
Molecular Weight	409.4 g/mol
XLogP3	2.1
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	1
Exact Mass	409.16625107 g/mol
Monoisotopic Mass	409.16625107 g/mol
Topological Polar Surface Area	122 Å²
Heavy Atom Count	30
Formal Charge	0
Complexity	687
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1